2020
PATIENT PHENOTYPES AND SGLT-2 INHIBITION IN TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL
Sharma A, Ofstad A, Ahmad T, Zinman B, Zwiener I, Fitchett D, Wanner C, George J, Hantel S, Desai N, Mentz R. PATIENT PHENOTYPES AND SGLT-2 INHIBITION IN TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2020, 36: s71. DOI: 10.1016/j.cjca.2020.07.143.Peer-Reviewed Original Research
2016
PATTERNS OF ASPIRIN UTILIZATION AND OUTCOMES AMONG PATIENTS WITH DIABETES MELLITUS: A PROPENSITY SCORE MATCHED ANALYSIS FROM THE SAVOR-TIMI 53 TRIAL
Desai N, Scirica B, Steg P, McGuire D, Mosenzon O, Im K, Raz I, Braunwald E, Bhatt D. PATTERNS OF ASPIRIN UTILIZATION AND OUTCOMES AMONG PATIENTS WITH DIABETES MELLITUS: A PROPENSITY SCORE MATCHED ANALYSIS FROM THE SAVOR-TIMI 53 TRIAL. Journal Of The American College Of Cardiology 2016, 67: 2099. DOI: 10.1016/s0735-1097(16)32100-3.Peer-Reviewed Original Research